Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
|Title:||Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers||Authors:||Schito, Luana; Rey, Sergio; Xu, Ping; et al.||Permanent link:||http://hdl.handle.net/10197/12323||Date:||7-Sep-2020||Online since:||2021-07-12T15:31:37Z||Abstract:||Conventional maximum‐tolerated dose (MTD) chemotherapy relies on periodic, massive cancer cell ablation events followed by treatment‐free intermissions, stereotypically resulting in resistance, relapse, and mortality. Furthermore, MTD chemotherapy can promote metastatic dissemination via activation of a transcriptional program dependent on hypoxia‐inducible factor (HIF)‐1α and (HIF)‐2α (hereafter referred to as HIFα). Instead, frequent low‐dose metronomic (LDM) chemotherapy displays less adverse effects while preserving significant pre‐clinical anticancer activity. Consequently, we hereby compared the effect of MTD or LDM chemotherapy upon HIFα in models of advanced, metastatic colon and breast cancer. Our results revealed that LDM chemotherapy could offset paralog‐specific, MTD‐dependent HIFα induction in colon cancers disseminating to the liver and lungs, while limiting HIFα and hypoxia in breast cancer lung metastases. Moreover, we assessed the translational significance of HIFα activity in colorectal and breast TCGA/microarray data, by developing two compact, 11‐gene transcriptomic signatures allowing the stratification/identification of patients likely to benefit from LDM and/or HIFα‐targeting therapies. Altogether, these results suggest LDM chemotherapy as a potential maintenance strategy to stave off HIFα induction within the intra‐metastatic tumor microenvironment.||Funding Details:||University College Dublin||Funding Details:||Canadian Institutes of Health Research (CIHR
Canadian Breast Cancer Foundation
|Type of material:||Journal Article||Publisher:||EMBO Press||Journal:||EMBO Molecular Medicine||Volume:||12||Issue:||9||Copyright (published version):||2020 the Authors||Keywords:||Breast cancer; Colon cancer; HIF-1; Hypoxia; Low-dose metronomic||DOI:||10.15252/emmm.201911416||Language:||en||Status of Item:||Peer reviewed||ISSN:||1757-4676||This item is made available under a Creative Commons License:||https://creativecommons.org/licenses/by/3.0/ie/|
|Appears in Collections:||Conway Institute Research Collection|
Medicine Research Collection
Show full item record
If you are a publisher or author and have copyright concerns for any item, please email firstname.lastname@example.org and the item will be withdrawn immediately. The author or person responsible for depositing the article will be contacted within one business day.